Tuesday, October 28, 2008 6:27:42 PM
Newton, Mass.-based Clinical Data (Nasdaq: CLDA) said the acquisition of Avalon Pharmaceuticals (Nasdaq: AVRX) in Germantown, Md., will help expand its cancer business with technology to help identify both new diagnostics and treatments.
The price is based on the 15-day volume weighted average price of $12.49 for Clinical Data’s common stock through Oct. 27.
Clinical Data buys rival for $10M in stock
The agreement also entailed Clinical Data completing a private placement of nearly 3.4 million shares of Avalon’s common stock. Clinical Data also loaned Avalon $3 million, and paid Avalon $1 million in exchange for a global, exclusive license to that company’s technology for drug and biomarker discovery. A biomarker can indicate the activity or likelihood of a certain disease such as cancer.
Late in September, Clinical Data negotiated a $25 million private placement to handle day-to-day working capital.
The company is developing new biotechnology treatments and also tests to help predict drug safety and effectiveness.
Clinical Data’s headquarters will remain in Newton. The company employs about 300 people around the world.
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM